(Q40738194)

English

213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model

scientific article published on April 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model (English)

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

1 reference

based on heuristic

inferred from title

cancer cell line

1 reference

based on heuristic

inferred from title

author name string

Y Li

1

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

S M A Rizvi

2

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

M Ranson

3

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

B J Allen

4

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

language of work or name

0 references

publication date

1 April 2002

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

86

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

7

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

1197-1203

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6600179

0 references

In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364168

24 September 2017

An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364168

24 September 2017

Cancer statistics, 2000.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364168

24 September 2017

Radioimmunotherapy of micrometastases in lung with vascular targeted 213Bi

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364168

24 September 2017

Prevention of metastasis by inhibition of the urokinase receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364168

24 September 2017

The complexity of DNA damage: relevance to biological consequences

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364168

24 September 2017

Biological and clinical aspects of plasminogen activator inhibitor type 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364168

24 September 2017

Directed plasminogen activation at the surface of normal and malignant cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364168

24 September 2017

Haemodynamic and Transport Barriers to the Treatment of Solid Tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364168

24 September 2017

Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364168

24 September 2017

Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364168

25 September 2017

Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364168

25 September 2017

The urokinase-type plasminogen activator system in cancer metastasis: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364168

17 June 2018

Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364168

17 June 2018

Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364168

17 June 2018

In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364168

19 August 2018

In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/11953871

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence for a general relationship between the induced level of DNA double-strand breakage and cell-killing after X-irradiation of mammalian cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/11953871

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: the potential role of terbium-149

1 reference

https://pubmed.ncbi.nlm.nih.gov/11953871

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radioimmunotherapy with alpha-emitting nuclides

1 reference

https://pubmed.ncbi.nlm.nih.gov/11953871

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry

1 reference

https://pubmed.ncbi.nlm.nih.gov/11953871

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Can alpha-immunotherapy succeed where other systemic modalities have failed?

1 reference

https://pubmed.ncbi.nlm.nih.gov/11953871

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radioimmunoconjugates for targeted alpha therapy of malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/11953871

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

What's hot in the prostate?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600179

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BJC.6600179

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40738194&oldid=1967147925"